Clinical Trials Logo

Hepatic Carcinoma clinical trials

View clinical trials related to Hepatic Carcinoma.

Filter by:

NCT ID: NCT03013712 Recruiting - Prostate Cancer Clinical Trials

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer

CARTEPC
Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.

NCT ID: NCT02834780 Completed - Clinical trials for Hepatocellular Carcinoma

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Start date: December 28, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.

NCT ID: NCT02352935 Completed - Hepatic Carcinoma Clinical Trials

Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be recorded.

NCT ID: NCT02332551 Completed - Hepatic Carcinoma Clinical Trials

Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma close to the gallbladder, also Progress Free Survival (PFS) will be recorded.

NCT ID: NCT01770431 Completed - Hepatic Carcinoma Clinical Trials

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

Start date: August 2011
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.

NCT ID: NCT01760616 Terminated - Hepatic Carcinoma Clinical Trials

Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

Start date: November 7, 2011
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.

NCT ID: NCT01350726 Recruiting - Cirrhosis Clinical Trials

Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan

GSA
Start date: January 2008
Phase: N/A
Study type: Observational

The aims of this study were divided into three parts: 1. To develop a new software to carry out the functional-three- dimensional-reconstruction of the liver by 99mTc-GSA-SPECT scintigraphy 2. To probe a new dynamic model of the metabolism of the 99mTc-GSA. 3. To evaluate the liver function by 99mTc-GSA-SPECT scintigraphy before surgical treatment. Study design: 1. Collectivity type: Prospective,randomized, controlled, multi-central clinical study. 2. Patients: The subjects were from different hospitals including: Peking Union Medical College Hospital (PUMCH). Study arrangement: This study was consisted of three parts:

NCT ID: NCT00884520 Completed - Lung Cancer Clinical Trials

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

VM4-037
Start date: April 2009
Phase: Phase 0
Study type: Interventional

Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design: Exploratory, open label, nonrandomized, multi-center study Duration: Three visits - one screening, one imaging, and one follow-up visit at 24 hours post-dose Procedures: Informed consent, collection of demographic information and medical history, physical examinations, vital signs, 12-lead ECGs, routine blood tests to assess major organ functions, complete blood counts and clinical chemistries for safety, blood sample for CA-IX assay, pre-dose and post-dose blood samples for metabolite analysis, dosing with [F-18]VM4-037, PET imaging scan, dosimetry estimation (normals), urine collections (normals), tumor immunohistochemistry with CA-IX biomarker, follow up to imaging to collect adverse events Subjects: Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria